BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 29068800)

  • 1. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.
    Ghaneh P; Kleeff J; Halloran CM; Raraty M; Jackson R; Melling J; Jones O; Palmer DH; Cox TF; Smith CJ; O'Reilly DA; Izbicki JR; Scarfe AG; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Padbury R; Shannon J; Dervenis C; Glimelius B; Deakin M; Anthoney A; Lerch MM; Mayerle J; Oláh A; Rawcliffe CL; Campbell F; Strobel O; Büchler MW; Neoptolemos JP;
    Ann Surg; 2019 Mar; 269(3):520-529. PubMed ID: 29068800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.
    Jones RP; Psarelli EE; Jackson R; Ghaneh P; Halloran CM; Palmer DH; Campbell F; Valle JW; Faluyi O; O'Reilly DA; Cunningham D; Wadsley J; Darby S; Meyer T; Gillmore R; Anthoney A; Lind P; Glimelius B; Falk S; Izbicki JR; Middleton GW; Cummins S; Ross PJ; Wasan H; McDonald A; Crosby T; Ting Y; Patel K; Sherriff D; Soomal R; Borg D; Sothi S; Hammel P; Lerch MM; Mayerle J; Tjaden C; Strobel O; Hackert T; Büchler MW; Neoptolemos JP;
    JAMA Surg; 2019 Nov; 154(11):1038-1048. PubMed ID: 31483448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial.
    Neoptolemos JP; Stocken DD; Dunn JA; Almond J; Beger HG; Pederzoli P; Bassi C; Dervenis C; Fernandez-Cruz L; Lacaine F; Buckels J; Deakin M; Adab FA; Sutton R; Imrie C; Ihse I; Tihanyi T; Olah A; Pedrazzoli S; Spooner D; Kerr DJ; Friess H; Büchler MW;
    Ann Surg; 2001 Dec; 234(6):758-68. PubMed ID: 11729382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
    Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
    J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective assessment of resection margin status following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma after standardisation of margin definitions.
    Pine JK; Haugk B; Robinson SM; Darne A; Wilson C; Sen G; French JJ; White SA; Manas DM; Charnley RM
    Pancreatology; 2020 Apr; 20(3):537-544. PubMed ID: 31996296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of margin status determined by the one-millimeter rule on tumor recurrence and survival following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
    Nitta T; Nakamura T; Mitsuhashi T; Asano T; Okamura K; Tsuchikawa T; Tamoto E; Murakami S; Noji T; Kurashima Y; Ebihara Y; Nakanishi Y; Shichinohe T; Hirano S
    Surg Today; 2017 Apr; 47(4):490-497. PubMed ID: 27677294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy.
    Fischer R; Breidert M; Keck T; Makowiec F; Lohrmann C; Harder J
    Saudi J Gastroenterol; 2012; 18(2):118-21. PubMed ID: 22421717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. R Status is a Relevant Prognostic Factor for Recurrence and Survival After Pancreatic Head Resection for Ductal Adenocarcinoma.
    Crippa S; Giannone F; Schiavo Lena M; Belfiori G; Partelli S; Tamburrino D; Delpini R; Pagnanelli M; Pecorelli N; Balzano G; Doglioni C; Falconi M
    Ann Surg Oncol; 2021 Aug; 28(8):4602-4612. PubMed ID: 33393031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of resection margin status on recurrence pattern and survival in distal pancreatectomy for left-sided pancreatic ductal adenocarcinoma.
    Kwon J; Lee SR; Park SY; Lee JH; Song KB; Hwang DW; Shin JH; Kim SC
    J Hepatobiliary Pancreat Sci; 2023 May; 30(5):633-643. PubMed ID: 36380718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic Cancer Surgery: The New R-status Counts.
    Strobel O; Hank T; Hinz U; Bergmann F; Schneider L; Springfeld C; Jäger D; Schirmacher P; Hackert T; Büchler MW
    Ann Surg; 2017 Mar; 265(3):565-573. PubMed ID: 27918310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
    Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
    BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Review.
    Datta J; Willobee BA; Ryon EL; Shah MM; Drebin JA; Kooby DA; Merchant NB
    JAMA Surg; 2021 May; 156(5):489-495. PubMed ID: 33533898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery.
    Tummers WS; Groen JV; Sibinga Mulder BG; Farina-Sarasqueta A; Morreau J; Putter H; van de Velde CJ; Vahrmeijer AL; Bonsing BA; Mieog JS; Swijnenburg RJ
    Br J Surg; 2019 Jul; 106(8):1055-1065. PubMed ID: 30883699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy for adenocarcinoma arising from intraductal papillary mucinous neoplasia: multicentre ADENO-IPMN study.
    Lucocq J; Hawkyard J; Haugk B; Mownah O; Menon K; Furukawa T; Inoue Y; Hirose Y; Sasahira N; Feretis M; Balakrishnan A; Ceresa C; Davidson B; Pande R; Dasari B; Tanno L; Karavias D; Helliwell J; Young A; Nunes Q; Urbonas T; Silva M; Gordon-Weeks A; Barrie J; Gomez D; Van Laarhoven S; Robertson F; Nawara H; Doyle J; Bhogal R; Harrison E; Roalso M; Ciprani D; Aroori S; Ratnayake B; Koea J; Capurso G; Bellotti R; Stättner S; Alsaoudi T; Bhardwaj N; Rajesh S; Jeffery F; Connor S; Cameron A; Jamieson N; Sheen A; Mittal A; Samra J; Gill A; Roberts K; Søreide K; Pandanaboyana S
    Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38659247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma: Updates From a French Prospective Multicenter Study.
    Delpero JR; Jeune F; Bachellier P; Regenet N; Le Treut YP; Paye F; Carrere N; Sauvanet A; Adham M; Autret A; Poizat F; Turrini O; Boher JM
    Ann Surg; 2017 Nov; 266(5):787-796. PubMed ID: 28953554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail.
    Hank T; Hinz U; Tarantino I; Kaiser J; Niesen W; Bergmann F; Hackert T; Büchler MW; Strobel O
    Br J Surg; 2018 Aug; 105(9):1171-1181. PubMed ID: 29738626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
    Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
    PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma.
    Jamieson NB; Foulis AK; Oien KA; Going JJ; Glen P; Dickson EJ; Imrie CW; McKay CJ; Carter R
    Ann Surg; 2010 Jun; 251(6):1003-10. PubMed ID: 20485150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microscopic resection margin status in pancreatic ductal adenocarcinoma - A nationwide analysis.
    Daamen LA; van Goor IWJM; Schouten TJ; Dorland G; van Roessel SR; Besselink MG; Bonsing BA; Bosscha K; Brosens LAA; Busch OR; van Dam RM; Fariña Sarasqueta A; Festen S; Groot Koerkamp B; van der Harst E; de Hingh IHJT; Intven MPW; Kazemier G; de Meijer VE; Nieuwenhuijs VB; Raicu GM; Roos D; Schreinemakers JMJ; Stommel MWJ; van Velthuysen MF; Verheij J; Verkooijen HM; van Santvoort HC; Molenaar IQ;
    Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):708-716. PubMed ID: 33323293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microscopically positive (R1) resections do not affect survival in pancreatic head cancer.
    Mois E; Graur F; Al-Hajjar N; Zaharie F; Bartos A; Bodea R; Zaharie T; Rusu I; Iancu C
    Ann Ital Chir; 2017; 88():491-496. PubMed ID: 29339587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.